MorphoSys, Novartis deal

The partners added MorphoSys' Ylanthia and Slonomics technology for antibody optimization to a 2007 deal granting Novartis exclusive access to MorphoSys' HuCAL antibody technology. The companies will cross-license future improvements and have decided to waive existing co-development options. The collaboration will continue until 2017. Novartis will continue to fund research at MorphoSys and annual license fees. The partners declined to disclose financial terms (see BioCentury, Dec. 10, 2007). ...